Cinclus Pharma Holding AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Sep '24 Sep 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	5.96	10.57	-
Revenue Growth (YoY)	-	-43.63%	-	-
Gross Profit	-	5.96	10.57	-
Selling, General & Admin	35.79	39.56	64.12	14.45
Research & Development	116.55	166.68	157.18	69.82
Operating Expenses	151.81	206.24	221.3	84.27
Operating Income	-151.81	-200.28	-210.73	-84.27
Interest Expense	-	-7.45	-0.08	-0.01
Interest & Investment Income	4.81	3.03	1.18	-
Currency Exchange Gain (Loss)	-10.49	-10.49	-21.39	8.01
Other Non Operating Income (Expenses)	0.58	0.58	0	0
Pretax Income	-156.91	-214.61	-231.01	-76.27
Income Tax Expense	1	0.51	18.06	-
Net Income	-157.91	-215.12	-249.07	-76.27
Net Income to Common	-157.91	-215.12	-249.07	-76.27
Shares Outstanding (Basic)	32	26	23	21
Shares Outstanding (Diluted)	32	26	23	21
Shares Change (YoY)	38.66%	13.81%	9.26%	-
EPS (Basic)	-4.94	-8.20	-10.81	-3.62
EPS (Diluted)	-4.94	-8.20	-10.81	-3.62
Free Cash Flow	-162.88	-209.19	-192.08	-75.48
Free Cash Flow Per Share	-5.10	-7.98	-8.33	-3.58
Gross Margin	-	100.00%	100.00%	-
Operating Margin	-	-3360.98%	-1993.45%	-
Profit Margin	-	-3609.97%	-2356.20%	-
Free Cash Flow Margin	-	-3510.42%	-1817.01%	-
EBITDA	-151.7	-200.25	-210.69	-84.26
D&A For EBITDA	0.11	0.03	0.04	0.01
EBIT	-151.81	-200.28	-210.73	-84.27

Source: S&P Capital IQ. Standard template. Financial Sources.